Humanized Antibody Fragment for Prion Diseases
Author Information
Author(s): Nives Škrlj, Tanja Vranac, Mara Popović, Vladka Čurin Šerbec, Marko Dolinar
Primary Institution: University of Ljubljana, Slovenia
Hypothesis
Can a humanized single-chain variable antibody fragment maintain the binding affinity and specificity of the original murine antibody while reducing immunogenicity?
Conclusion
The humanized scFv V5B2 retains the binding properties of the original murine antibody and may serve as a potential therapeutic reagent for prion diseases.
Supporting Evidence
- The humanized scFv V5B2 was designed to minimize immunogenicity while retaining binding specificity.
- Both murine and humanized scFvs specifically label PrPSc deposits in brain tissue.
- The final humanized variant showed comparable binding affinity to the original murine antibody.
Takeaway
Scientists made a version of an antibody that can recognize a harmful protein in the brain without causing problems in humans. This could help treat diseases caused by that protein.
Methodology
The study involved humanizing a murine monoclonal antibody by introducing mutations to reduce immunogenicity while maintaining binding affinity, followed by expression and purification of the humanized scFv.
Limitations
The study does not provide clinical data on the immunogenicity of the humanized antibody.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website